ASCO 2019 | MRD testing in AML: the next steps in 2019

Name: MRD testing in AML: the next steps in 2019
Uploaded: 2019-06-01T22:54:28.000Z
Duration: 2 min 36 s
Description: Measurable residual disease (MRD) has proved to have potential in testing for hematological malignancies including acute myeloid leukemia (AML). Here, Michael Heuser, MD, of Hannover Medical School, Hanover, Germany, delivers the next steps going forward in MRD testing in 2019. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

Michael Heuser • 1 Jun 2019

ASCO 2019

Acute Myeloid Leukemia Leukemia

Measurable residual disease (MRD) has proved to have potential in testing for hematological malignancies including acute myeloid leukemia (AML). Here, Michael Heuser, MD, of Hannover Medical School, Hanover, Germany, delivers the next steps going forward in MRD testing in 2019. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.